Challenges and innovations in CAR-T cell therapy: a comprehensive analysis
J Luo, X Zhang - Frontiers in Oncology, 2024 - pmc.ncbi.nlm.nih.gov
Recent years have seen a marked increase in research on chimeric antigen receptor T
(CAR-T) cells, with specific relevance to the treatment of hematological malignancies. Here …
(CAR-T) cells, with specific relevance to the treatment of hematological malignancies. Here …
Advances in targeting tumor microenvironment for immunotherapy
L Wang, L Zhang, Z Zhang, P Wu, Y Zhang… - Frontiers in …, 2024 - frontiersin.org
The tumor microenvironment (TME) provides essential conditions for the occurrence,
invasion, and spread of cancer cells. Initial research has uncovered immunosuppressive …
invasion, and spread of cancer cells. Initial research has uncovered immunosuppressive …
[HTML][HTML] Breaking Boundaries: Immunotherapy for Myeloid Malignancies
Simple Summary Patients with myeloid malignancies (blood cancers such as leukemia and
myelodysplastic syndromes) that have returned or worsened despite chemotherapy or a …
myelodysplastic syndromes) that have returned or worsened despite chemotherapy or a …
The potential of siglecs and sialic acids as biomarkers and therapeutic targets in tumor immunotherapy
Simple Summary Sialic acid dysregulation is closely associated with the occurrence and
development of tumors. Sialic acid-binding immunoglobulin-like lectins (Siglecs) are a class …
development of tumors. Sialic acid-binding immunoglobulin-like lectins (Siglecs) are a class …
[HTML][HTML] The Wilms' Tumor Suppressor WT1 in Cardiomyocytes: Implications for Cardiac Homeostasis and Repair
S Díaz del Moral, N Wagner, KD Wagner - Cells, 2024 - mdpi.com
The Wilms' tumor suppressor WT1 is essential for the development of the heart, among other
organs such as the kidneys and gonads. The Wt1 gene encodes a zinc finger transcription …
organs such as the kidneys and gonads. The Wt1 gene encodes a zinc finger transcription …
Evolving strategies for addressing CAR T-cell toxicities
The field of chimeric antigen receptor (CAR) T-cell therapy has grown from a fully
experimental concept to now boasting a multitude of treatments including six FDA-approved …
experimental concept to now boasting a multitude of treatments including six FDA-approved …
Finding potential targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia
Acute myeloid leukemia (AML) is a hostile hematological malignancy under great danger of
relapse and poor long-term survival rates, despite recent therapeutic advancements. To deal …
relapse and poor long-term survival rates, despite recent therapeutic advancements. To deal …
Honing CAR T cells to tackle acute myeloid leukemia
S Haubner, M Subklewe, M Sadelain - Blood Journal, 2024 - ashpublications.org
Acute myeloid leukemia (AML) remains a dismal disease with poor prognosis, particularly in
the relapsed/refractory (r/r) setting. Chimeric antigen receptor (CAR) therapy has yielded …
the relapsed/refractory (r/r) setting. Chimeric antigen receptor (CAR) therapy has yielded …
Molecular mechanisms of Y chromosome loss and UTY gene activity
The Y chromosome is considered a sex-determining chromosome, this is the prevailing
stereotype. Large parts of the Y chromosome are also considered genetically as noncoding …
stereotype. Large parts of the Y chromosome are also considered genetically as noncoding …
[HTML][HTML] FLT3 mutation-related immune checkpoint molecule absent in melanoma 2 (AIM2) contributes to immune infiltration in pediatric and adult acute myeloid …
J Zhao, Y Cui, H Zhou, D Zhou, Z Che… - Translational …, 2024 - pmc.ncbi.nlm.nih.gov
Background The use of FMS-like tyrosine kinase 3 (FLT3) as a crucial target for kinase
inhibitors is well established, but its association with immune infiltration remains unclear …
inhibitors is well established, but its association with immune infiltration remains unclear …